goserelin acetate 3-month extended-release microspheres (LY01022) / Luye Group - LARVOL DELTA

Efficacy of triplet therapy based on organoid drug sensitivity testing in lung metastatic hormone-sensitive prostate cancer. (ASCO 2025) - "The triple regimen of goserelin acetate extended-release microspheres in combination with rezvilutamide and docetaxel demonstrated encouraging outcomes in HSPC with lung metastasis. The construction of organoid and drug sensitivity assays holds great potential in facilitating more precise screening of suitable treatment regimens for individual patients."

Clinical • Metastases • Anemia • Constipation • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Musculoskeletal Pain • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

The impact of different formulations of goserelin on testosterone suppression in patients with prostate cancer: A real world observational research. (ASCO 2025) - " This analysis was conducted in real-world clinics, focusing on patients diagnosed with prostate cancer who had initiated goserelin acetate extended-release microspheres for injection dosed every 4 weeks (dosing intervals of 28, 56, and 84 days) and goserelin acetate sustained-release depot dosed every 12 weeks (dosing intervals of 84, 168, and 252 days) to compare the efficacy of different dosage forms of goserelin and the effect of dosing delay on testosterone control. The present study examined the impact of delayed injection of goserelin on testosterone control. It is imperative to direct greater attention to the development of effective follow-up strategies and the enhancement of adherence to androgen deprivation therapy in prostate cancer patients, with a view to improving clinical outcomes."

Clinical • Real-world • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Goserelin Extended-Release Microspheres versus Sustained-Release Implant in Prostate Cancer: Real-World Evidence on Efficacy and Safety (ChiCTR) - P4 | N=50 | Not yet recruiting | Sponsor: Aerospace Center Hospital; Aerospace Center Hospital

HEOR • New P4 trial • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Preparation and in vitro/in vivo evaluation of uniform-sized Goserelin-loaded sustained release microspheres. (PubMed, J Control Release) - "In the animal model(administered dose, 2.4 mg·Kg-1), goserelin long-acting sustained release microspheres sustained release for over 32 days, maintaining effective concentrations above 2 ng·mL-1, and effectively reduced serum testosterone concentrations to castration levels (<1.0 ng·mL-1) by day 4, maintaining this inhibition for up to 21 days, exhibiting comparable efficacy to the positive control group. In vivo release kinetics analysis revealed that goserelin-loaded sustained release microspheres exhibited a release pattern dominated by diffusion with corrosion assistance in vivo. In summary, the systematic and comprehensive evaluation of uniform-sized goserelin-loaded sustained release microspheres has highlighted their excellent translational potential, and the study herein may provide new strategies and ideas for the development of microsphere dosage forms."

Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management. (PubMed, Curr Oncol) - "Recent studies have affirmed the efficacy and safety of long-acting (LA) goserelin 10.8 mg every 12 weeks, offering comparable outcomes to monthly injections. With the recent approval of goserelin 10.8 mg LA by Health Canada on 6 May 2024, for use in breast cancer, Canada is the latest to join over 60 countries worldwide to expand the accepted indications for goserelin LA and ensure its availability to potentially enhance healthcare delivery, patient care, and breast cancer outcomes. Goserelin LA offers premenopausal patients a means to more effectively manage the constraints imposed by breast cancer treatment and its impact on survivorship."

Journal • Review • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor

GOSERELIN INHIBITING UPTAKE ON SODIUM PERTECHNETATE Tc-99M THYROID SCAN: A CASE REPORT. (PubMed, Ann Ib Postgrad Med) - "Thyroiditis may be induced by goserelin (a long acting analogue of gonadotropin - releasing hormone) prescribed for the treatment of pain and bleeding of endometriosis. This case report highlights a rare instance of a middle-aged woman with symptomatic toxic goitre whose sodium pertechnetate Tc-99m thyroid scan uptake was inhibited by goserelin therapy. Medical personnel caring for patients on goserelin need to be aware of the possibility of it affecting thyroid function."

Journal • Endocrine Disorders • Endometriosis • Gynecology • Pain • Women's Health

Luye Pharma : 3-month Long-acting Goserelin Microspheres Approved for Clinical Trials in China (Market Screener) - "uye Pharma Group today announced that its 3-month long-acting Goserelin Acetate Extended-release Microspheres for Injection (LY01022), an innovative anticancer formulation developed by the company itself, has been approved by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) for clinical trials, intended for treating prostate cancer and breast cancer that can be treated with hormones."

New trial • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer